File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Solube E-cadherin is an independent pretherapeutic factor for long term survival in gastric cancer

TitleSolube E-cadherin is an independent pretherapeutic factor for long term survival in gastric cancer
Authors
Issue Date2003
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
The 2003 Asia Pacific Digestive Week (APDW), Singapore, 27-30 September 2003. In Journal of Gastroenterology and Hepatology, 2003, v. 18 suppl. 1, p. A27, abstract no. 8 How to Cite?
AbstractINTRODUCTION: Gastric cancer remains the second leading cause of cancer-related deaths in the world, but a satisfactory tumor marker is currently unavailable for gastric cancer. Soluble E-cadherin has recently been found to have prognostic value in gastric cancer.We aim at evaluating whether pretherapeutic serum soluble E-cadherin is an independent factor predicting long-term survival in gastric cancer. PATIENTS AND METHODS: One hundred and sixteen patients with histology proven gastric adenocarcinoma were included. Pretherapeutic serum was collected and soluble E-cadherin was assayed using a commercially available ELISA kit. The patients were followed up prospectively at the outpatient clinic. RESULTS: There were 75 men and 41 women with a mean age of 66 ± 14 years. Forty-eight percent of tumors were located in the gastric antrum. The median survival was 11 months. The mean pretherapeutic value of soluble E-cadherin was 9159 ng/mL (range, 6002–10025 ng/mL), and that of CEA was 11 ng/mL (range, 0.3–4895 ng/mL). On multivariate analysis, soluble E-cadherin is an independent factor predicting long-term survival. Ninety percent of patients with serum level of E-cadherin greater than 10000 ng/mL had survival less than 3 years (P = 0.009). CONCLUSIONS: Soluble E-cadherin is a potentially valuable pretherapeutic prognostic factor in patients with gastric cancer.
DescriptionThis free journal suppl. entitled: Abstracts from the Asia Pacific Digestive Week 2003
Persistent Identifierhttp://hdl.handle.net/10722/101812
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.179

 

DC FieldValueLanguage
dc.contributor.authorChan, AOO-
dc.contributor.authorChu, KM-
dc.contributor.authorLam, SK-
dc.contributor.authorWong, BCY-
dc.contributor.authorKwok, KF-
dc.contributor.authorLaw, SYK-
dc.contributor.authorHui, WM-
dc.contributor.authorYueng, YH-
dc.contributor.authorWong, J-
dc.date.accessioned2010-09-25T20:05:23Z-
dc.date.available2010-09-25T20:05:23Z-
dc.date.issued2003-
dc.identifier.citationThe 2003 Asia Pacific Digestive Week (APDW), Singapore, 27-30 September 2003. In Journal of Gastroenterology and Hepatology, 2003, v. 18 suppl. 1, p. A27, abstract no. 8-
dc.identifier.issn0815-9319-
dc.identifier.urihttp://hdl.handle.net/10722/101812-
dc.descriptionThis free journal suppl. entitled: Abstracts from the Asia Pacific Digestive Week 2003-
dc.description.abstractINTRODUCTION: Gastric cancer remains the second leading cause of cancer-related deaths in the world, but a satisfactory tumor marker is currently unavailable for gastric cancer. Soluble E-cadherin has recently been found to have prognostic value in gastric cancer.We aim at evaluating whether pretherapeutic serum soluble E-cadherin is an independent factor predicting long-term survival in gastric cancer. PATIENTS AND METHODS: One hundred and sixteen patients with histology proven gastric adenocarcinoma were included. Pretherapeutic serum was collected and soluble E-cadherin was assayed using a commercially available ELISA kit. The patients were followed up prospectively at the outpatient clinic. RESULTS: There were 75 men and 41 women with a mean age of 66 ± 14 years. Forty-eight percent of tumors were located in the gastric antrum. The median survival was 11 months. The mean pretherapeutic value of soluble E-cadherin was 9159 ng/mL (range, 6002–10025 ng/mL), and that of CEA was 11 ng/mL (range, 0.3–4895 ng/mL). On multivariate analysis, soluble E-cadherin is an independent factor predicting long-term survival. Ninety percent of patients with serum level of E-cadherin greater than 10000 ng/mL had survival less than 3 years (P = 0.009). CONCLUSIONS: Soluble E-cadherin is a potentially valuable pretherapeutic prognostic factor in patients with gastric cancer.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.relation.ispartofJournal of Gastroenterology and Hepatology-
dc.titleSolube E-cadherin is an independent pretherapeutic factor for long term survival in gastric cancer-
dc.typeConference_Paper-
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=18&issue=9 suppl&spage=A27&epage=&date=2003&atitle=Solube+E-cadherin+is+an+independent+pretherapeutic+factor+for+long+term+survival+in+gastric+canceren_HK
dc.identifier.emailChan, AOO: aoochan@hku.hk-
dc.identifier.emailChu, KM: chukm@hkucc.hku.hk-
dc.identifier.emailLam, SK: hrmelsk@hkucc.hku.hk-
dc.identifier.emailWong, BCY: bcywong@hku.hk-
dc.identifier.emailLaw, SYK: slaw@hku.hk-
dc.identifier.emailHui, WM: hrmehwm@hkucc.hku.hk-
dc.identifier.emailYueng, YH: yhyueng@hkucc.hku.hk-
dc.identifier.emailWong, J: jwong@hkucc.hku.hk-
dc.identifier.authorityChu, KM=rp00435-
dc.identifier.authorityWong, BCY=rp00429-
dc.identifier.authorityLaw, SYK=rp00437-
dc.identifier.authorityWong, J=rp00322-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1046/j.1440-1746.18.s1.1.x-
dc.identifier.hkuros99258-
dc.identifier.volume18-
dc.identifier.issuesuppl. 1-
dc.identifier.spageA27, abstract no. 8-
dc.identifier.epageA27, abstract no. 8-
dc.publisher.placeAustralia-
dc.identifier.issnl0815-9319-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats